Effectiveness of netakimab in real clinical practice in patients with severe forms of psoriasis

Abstract

Psoriasis refers to genetically deterministic chronic inflammatory dermatoses, which are characterized by systemic immuno-mediated inflammatory response with preferential activation of the IL -23/-17 axis, growth deviation and keratinocyte differentiation.

Material and methods. There were 21 patients under supervision with moderate to severe plaque psoriasis. Nine (42.8 %) patients did not receive previous systemic therapy; 3 (14.2 %) patients received apremilast at a dose of 30 mg twice a day during a year, 4 (19.0 %) patients were prescribed methotrexate at a dose of 15 mg subcutaneously weekly, for at least a year; 5 (23.8 %) patients received secukinumab at 300 mg subcutaneously once every 4 weeks for a year. All patients had a lost of effect or had developed side effects, which determined a change in therapeutic tactics.

Results. Among the patients who were earlier not receiving treatment treatment after therapy with netakimab was started, the PASI index made 3.5 ± 1.1 (decrease by 94.4 %), the PASI index at the patients who were earlier receiving sekukinumab was 4.5 ± 1.1 (decrease by 81.9 %), among the patients who were earlier receiving the methotrexate the PASI index was 8.5 ± 1.3 (decrease by 89.9 %), at the patients who were earlier receiving apremilast the PASI index was 9.5 ± 2.1 (decrease by 86.3 %).

Conclusions. Improvement in skin symptoms was accompanied by improvement of patients’ quality of life. Thus, the DLQI decreased by 77.9 % in the group of patients who had not previously received systemic therapy, by 77.4 % and 76.4 % in patients who had previously received sekukinumab and methotrexate therapy, respectively, and by 85.2 % in the group of patients who had previously received apremilast.